5 reasons to invest in AcuCort
1. Innovative product – clear clinical benefit
Zeqmelit® is a fast-dissolving oral film – easy to carry and easy to use – that addresses a large patient need for acute and severe allergic reactions.
2. Low development risk – Zeqmelit® approved
Zeqmelit® is approved for sale in Sweden, Norway, Finland and Denmark with regulatory approvals and agreements with distributors.
3. Sales started – Sweden, Norway, Finland & Denmark
Zeqmelit® has been available in pharmacies in Sweden, Norway and Finland since the autumn of 2024 and since this summer in Denmark.
4. Large market – over USD 3 billion
Around 30% of the world’s population suffers from allergic symptoms. The potential market for Zeqmelit® is estimated to be worth more than USD 3 billion.
5. Competent team – Experienced board
The management and the Board of Directors have a broad and deep experience in commercializing new drugs.